EUVIMEDScopri EUVIMED
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudie

Impact of Continuation Versus Interruption of Oral Anticoagulation During TAVI on Health‐Related Quality of Life

Dirk Jan van Ginkel, Willem L Bor, Hugo M Aarts iD, Christophe Dubois, Ole De Backer, Maxim J P Rooijakkers iD, Liesbeth Rosseel, Leo Veenstra, Ronak Delewi, Jurriën M Ten Berg

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31457 ↗

At a glance

Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2025. Written by Dirk Jan van Ginkel and 9 co-authors. Institution: Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Major MEDLINE topics: Anticoagulants, Quality of Life, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. 30 references. Funded by: The POPular PAUSE TAVI trial (NCT04437303) was supported by grants from the Netherlands Organization for Health Research and Development and the St. Antonius R….

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

One‐third of patients undergoing TAVR have a concomitant indication for oral anticoagulation. The impact of continuation as compared to interruption of oral anticoagulation during TAVR on health‐related quality of life is unknown.

Aims

To investigate the impact of continuation as compared to interruption of oral anticoagulation on health‐related quality of life.

Methods

The POPular PAUSE TAVI (Periprocedural Continuation vs . Interruption of Oral Anticoagulant Drugs during Transcatheter Aortic Valve Implantation) trial was an international, open‐label, randomized, clinical trial performed at 22 European sites. Health‐related quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Short Form‐12 (SF‐12) before, and at 1 and 3 months after TAVR.

Results

A total of 8 patients were included: 431 were assigned to continuation and 427 to interruption of oral anticoagulation. Before TAVR, the mean overall KCCQ summary score was 53.6 (±26.0). At 1 month, the mean change in KCCQ summary score as compared to baseline was +11.4 points (95% confidence interval [CI] 8.0–14.8) in the continuation group and +12.2 points (95% CI 8.8–15.6) in the interruption group (difference −0.7 points; 95% CI −4.6 to 3.1). At 3 months, the mean change was +11.0 points (95% CI 7.3–14.6) versus +13.8 points (95% CI 10.2–17.4), respectively (difference −2.8 points; 95% CI −7.1 to 1.5). Mean changes in SF‐12 physical and mental component summary scores showed no differences between both groups at 1 and 3 months after TAVR.

Conclusions

In patients undergoing TAVR with a concomitant indication for oral anticoagulation, continuation as compared to interruption of oral anticoagulation during TAVR did not significantly impact health‐related quality of life up to 3 months after TAVR.

Subjects

MeSH terms (MEDLINE)

AnticoagulantsQuality of LifeTranscatheter Aortic Valve ReplacementAortic Valve StenosisAortic ValveHumansMaleFemaleAdministration, OralTime FactorsAged, 80 and overTreatment OutcomeAgedEuropeDrug Administration ScheduleRisk FactorsSurveys and Questionnaires

Author keywords

KCCQTAVIanticoagulationbleedingquality of lifestroke

Substances

Anticoagulants

Authors and institutions

  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium.
  • The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID profiles: Hugo M Aarts, Maxim J P Rooijakkers

Funding

  • The POPular PAUSE TAVI trial (NCT04437303) was supported by grants from the Netherlands Organization for Health Research and Development and the St. Antonius R…

Cite

APA

van Ginkel, D. J., Bor, W. L., Aarts, H. M., Dubois, C., Backer, O., Rooijakkers, M. J. P., Rosseel, L., Veenstra, L., Delewi, R., & Ten Berg, J. M. (2025). Impact of Continuation Versus Interruption of Oral Anticoagulation During TAVI on Health‐Related Quality of Life. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31457

Vancouver

van Ginkel DJ, Bor WL, Aarts HM, Dubois C, Backer O, Rooijakkers MJP, et al. Impact of Continuation Versus Interruption of Oral Anticoagulation During TAVI on Health‐Related Quality of Life. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31457

BibTeX
@article{vanGinkel2025,
  author = {van Ginkel, Dirk Jan and Bor, Willem L and Aarts, Hugo M and Dubois, Christophe and Backer, Ole De and Rooijakkers, Maxim J P and Rosseel, Liesbeth and Veenstra, Leo and Delewi, Ronak and Ten Berg, Jurriën M},
  title = {Impact of Continuation Versus Interruption of Oral Anticoagulation During TAVI on Health‐Related Quality of Life},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31457}
}
Start for free →